118 related articles for article (PubMed ID: 33420392)
21. Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review.
Chen Z; Lin Y; Qin Y; Qu H; Zhang Q; Li Y; Wen Y; Sun J; Tu P; Gao P; Wang Y
JAMA Dermatol; 2023 Oct; 159(10):1059-1067. PubMed ID: 37585188
[TBL] [Abstract][Full Text] [Related]
22. Pralatrexate and total skin electron beam therapy as bridging agents to allogeneic stem cell transplantation in severely treatment-refractory Sezary syndrome.
Truong K; Bhattacharyya A; Smee R; Kim J; Wells J
Int J Dermatol; 2023 Apr; 62(4):e219-e221. PubMed ID: 36683181
[No Abstract] [Full Text] [Related]
23. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
Papadavid E; Kapniari E; Pappa V; Nikolaou V; Iliakis T; Dalamaga M; Jonak C; Porkert S; Engelina S; Quaglino P; Ortiz-Romero PL; Vico C; Cozzio A; Dimitriou F; Guiron R; Guenova E; Hodak E; Bagot M; Scarisbrick J
Br J Dermatol; 2021 Nov; 185(5):1035-1044. PubMed ID: 34137025
[TBL] [Abstract][Full Text] [Related]
24. Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation.
Frederiks AJ; Creeper KJ; Spagnolo DV; Cannell P; Radeski D
Australas J Dermatol; 2021 Aug; 62(3):e400-e403. PubMed ID: 34028795
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome.
Zeng X; Xuan L; Fan Z; Zhang Y; Zhao K; Zhou Y; Xu J; Liu Q; Dai M
Exp Hematol Oncol; 2021 Aug; 10(1):44. PubMed ID: 34391477
[TBL] [Abstract][Full Text] [Related]
26. CRP Levels as a Prognostic Factor in Mycosis Fungoides.
Slutsky Bank E; Rozenblat M; Eytan O; Perelman M; Geller S; Sprecher E; Goldberg I
Acta Dermatovenerol Croat; 2022 Nov; 30(3):140-145. PubMed ID: 36812270
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001-2020.
Simeunovic H; Dickenmann M; Nabergoj M; Baldomero H; Masouridi-Levrat S; Nair G; Schanz U; Passweg J; Rovo A; Chalandon Y; Rebmann E
EJHaem; 2023 Feb; 4(1):262-265. PubMed ID: 36819181
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better.
Rebmann E; Nabergoj M; Grandjean B; Stakia P; Stern A; Medinger M; Masouridi-Levrat S; Dantin C; Schanz U; Baldomero H; Passweg J; Nair G; Rovo A; Chalandon Y
EJHaem; 2023 Feb; 4(1):258-261. PubMed ID: 36819159
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Graft
Franke GN; Dumann K; Jentzsch M; Monecke A; Doehring C; Nehring-Vucinic C; Schwind S; Niederwieser D; Platzbecker U; Ziemer M; Vucinic V
Front Oncol; 2021; 11():749691. PubMed ID: 34956873
[TBL] [Abstract][Full Text] [Related]
30. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry.
Ljungman P; Tridello G; Piñana JL; Ciceri F; Sengeloev H; Kulagin A; Mielke S; Yegin ZA; Collin M; Einardottir S; Lepretre SD; Maertens J; Campos A; Metafuni E; Pichler H; Folber F; Solano C; Nicholson E; Yüksel MK; Carlson K; Aguado B; Besley C; Byrne J; Heras I; Dignan F; Kröger N; Robin C; Khan A; Lenhoff S; Grassi A; Dobsinska V; Miranda N; Jimenez MJ; Yonal-Hindilerden I; Wilson K; Averbuch D; Cesaro S; Xhaard A; Knelange N; Styczynski J; Mikulska M; de la Camara R
Front Immunol; 2023; 14():1125824. PubMed ID: 36960069
[TBL] [Abstract][Full Text] [Related]
31. Economic analysis of allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Center of Tunisia.
Achour L; Drira C; Sboui MZ; Fazaa I; Soussi MA; Hammami S; Ben Othman T; Razgallah Khrouf M
J Mark Access Health Policy; 2023; 11(1):2236851. PubMed ID: 37576087
[No Abstract] [Full Text] [Related]
32. Current status and prospects of hematopoietic stem cell transplantation in China.
Wang X; Huang R; Zhang X; Zhang X
Chin Med J (Engl); 2022 Jun; 135(12):1394-1403. PubMed ID: 35866344
[TBL] [Abstract][Full Text] [Related]
33. Predicting Patient Death after Allogeneic Stem Cell Transplantation for Inborn Errors Using Machine Learning (PREPAD): A European Society for Blood and Marrow Transplantation Inborn Errors Working Party Study.
von Asmuth EGJ; Neven B; Albert MH; Mohseny AB; Schilham MW; Binder H; Putter H; Lankester AC
Transplant Cell Ther; 2023 Dec; 29(12):775.e1-775.e8. PubMed ID: 37709203
[TBL] [Abstract][Full Text] [Related]
34. The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications.
Mazzeo E; Rubino L; Buglione M; Antognoni P; Magrini SM; Bertoni F; Parmiggiani M; Barbieri P; Bertoni F
Rep Pract Oncol Radiother; 2014 Mar; 19(2):77-91. PubMed ID: 24936325
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Alexander T; Greco R
Bone Marrow Transplant; 2022 Jul; 57(7):1055-1062. PubMed ID: 35578014
[TBL] [Abstract][Full Text] [Related]
36. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis.
Luther M; Henes FO; Zabelina T; Massoud R; Janson D; Wolschke C; Klyuchnikov E; Gagelmann N; Fehse B; Adam G; Kröger N; Ayuk F
Bone Marrow Transplant; 2023 Jul; 58(7):755-761. PubMed ID: 37002409
[TBL] [Abstract][Full Text] [Related]
37. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.
Assaf C; Illidge TM; Waser N; He M; Li T; Zomas A; Bent-Ennakhil N; Little M; Ortiz-Romero PL; Pimpinelli N; Dalal M; Bagot M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067371
[TBL] [Abstract][Full Text] [Related]
38. Dupilumab-associated mycosis fungoides: a cross-sectional study.
Hamp A; Hanson J; Schwartz RA; Lambert WC; Alhatem A
Arch Dermatol Res; 2023 Nov; 315(9):2561-2569. PubMed ID: 37270763
[TBL] [Abstract][Full Text] [Related]
39. Perspectives on and Quality of Life in Skin of Color Patients With Mycosis Fungoides/Sézary Syndrome: A Qualitative Analysis.
Abraham J; Wei G; Desai SR; Chen PL; Seminario-Vidal L
Cureus; 2023 Jan; 15(1):e34054. PubMed ID: 36824562
[TBL] [Abstract][Full Text] [Related]
40. How I treat transplant-eligible patients with myelofibrosis.
Kröger N; Wolschke C; Gagelmann N
Blood; 2023 Nov; 142(20):1683-1696. PubMed ID: 37647853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
